Report #2862426

Received Oct 1, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: FL
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
COVID19	COVID19 (COVID19 (PFIZER-BIONTECH))	PFIZER\BIONTECH	1	—	—

Symptoms (2)

RashReaction to excipient

Symptom narrative

Rash after Comirnaty; agents contain polyethylene glycol; Rash after Comirnaty; agents contain polyethylene glycol; This is a spontaneous report received from a nurse from medical information team. A patient (age and gender not provided) received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation; polyethylene glycol [macrogol] (POLYETHYLENE GLYCOL [MACROGOL]). The patient's relevant medical history and concomitant medications were not reported. The following information was reported: REACTION TO EXCIPIENT (non-serious), RASH (non-serious), outcome "unknown" and all described as "Rash after Comirnaty; agents contain polyethylene glycol". Additional Information: The nurse was asking information the company has regarding cross allergy between Paxlovid and Comirnaty. The patient has rash after Comirnaty and EMR flagged Paxlovid for cross allergy because both agents contain polyethylene glycol. The information on the batch/lot number for BNT162b2 omicron (lp.8.1) will be requested and submitted if and when received.

Other medications

MACROGOL